Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Progress
To understand L3MBTL3, it is important to understand "readers" of the histone code, which are proteins binding methylated lysines. These proteins are important components in the epigenetic regulation of gene expression. They also play a role in modulating other proteins with methyl-lysine such as p53 and Rb. Compaction of chromatin and a repressed transcriptional state have been identified with recognition of methyl-lysine marks by MBT domains.
UNC1215 was discovered by the researchers as a potential chemical probe for the methyl-lysine (Kme) reading function of L3MBTL3. Specifically speaking, UNC1215 binds L3MBTL3 with a K(d) of 120 nM and is greater than 50-fold more potent toward L3MBTL3 compared with other members of the MBT family. Its selectivity against more than 200 other reader domains examined was not compromised. The 2:2 polyvalent mode of interaction between UNC1215 and L3MBTL3 was revealed by X-ray crystallography. It is discovered that the cellular mobility of GFP-L3MBTL3 fusion proteins could be increased through UNC1215. Moreover, a new Kme-dependent interaction between L3MBTL3 and BCLAF1(a protein associated with DNA damage repair and apoptosis) was revealed through usage of UNC1215(Fig. 1).
Fig. 1. X-ray crystal structure of the UNC1215-3MBT complex. (LI James et al, 2013)
Antagonists of MBT domains could serve as probes to interrogate the functional role of "readers" of the histone code. first using a chemi-luminescent assay and ITC to determine the structure of histone peptide-MBT complexes and their interaction with MBT domains, investigators then designed small-molecule MBT antagonists based on findings. They discovered ligands that antagonize native histone peptide binding, what is more, they displayed 5-fold stronger binding affinity to L3MBTL1 than its preferred histone peptide. They also defined the first cocrystal structure of a small molecule bound to L3MBTL1.
After the discovery of UNC1215 as a potent and selective chemical probe for the L3MBTL3 methyllysine reader domain, researchers further described the development of structure activity relationships (SAR) of a second series of potent L3MBTL3 antagonists. These proteins developed from the structure of the chemical probe UNC1215. As mentioned before, these compounds are selective for L3MBTL3 against a panel of methyl-lysine reader proteins, in particular the related MBT family proteins, L3MBTL1 and MBTD1. Through studying the co-crystal structure of L3MBTL3 along with one of the most potent compounds, it is revealed by the investigator that the L3MBTL3 dimer rotates about the dimer interface to accommodate ligand binding.
Based on the above mentioned findings, researchers took the study further to describe in vitro analysis of L3MBTL3 dimerization through its MBT domains. Results indicated that this dimerization occurs within a cellular context, in particular when the small molecule ligands are absent. More intriguingly, both in vitro and in cells, mutations occurred at the first and second MBT domains abrogated L3MBTL3 dimerization. These findings taken together provide a more solid foundation for the hypothesis, that L3MBTL3 interacts with methylated histone tails as a dimer. These results also offer an explanation for the presence of repeated MBT domains within L3MBTL3.
DNMT1 is considered as a major DNA methyl-transferase that preserves epigenetic inheritance of DNA methylation patterns during DNA replication. Researchers have reported that the methylated lysine 142 of DNMT1 is de-methylated by LSD1. It has been revealed that L3MBTL3 binds the K142-methylated DNMT1 and recruits a novel CRL4DCAF5 ubiquitin ligase to degrade DNMT1. LSD1 and PHF20L1 both act primarily during S phase. This is thought to prevent DNMT1 degradation by L3MBTL3-CRL4DCAF5. Deletion of L3MBTL3/MBT-1 in mouse can cause accumulation of DNMT1 protein, increase in genomic DNA methylation, along with late embryonic lethality. Results indicated that L3MBTL3-CRL4DCAF5 can modulate the methylation-dependent E2F1 degradation.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.